Lak HM, Chawla S, Chawla RD, et al. - According to this retrospective analysis, patients with severe aortic stenosis (AS) and concomitant liver cirrhosis who had transcatheter aortic valve implantation (TAVI) had similar outcomes as noncirrhotic peers.

• Between April 2015 and December 2018, patients with severe symptomatic AS who underwent transfemoral TAVI with a SAPIEN 3 valve at the institution were analyzed.

• Thirty-two patients with cirrhosis of the liver on imaging (including ultrasound and/or computed tomography) and patients with severe symptomatic AS who underwent transfemoral TAVI with a SAPIEN 3 valve were identified.

• Thirty-two of the 1,028 patients had liver cirrhosis, while 996 were in the control group without cirrhosis.

• The cirrhosis group's mean age was 74.5 years, compared with 81.2 years in the control group.

• Baseline variables were similar between the groups.

• Patients with cirrhosis had a similar 1-year mortality rate as the noncirrhotic group, as well as a lower 30-day new pacemaker rate after TAVI, a higher 30-day and 1-year readmission rate for heart failure, and a similar 1-year major adverse cardiac and cerebrovascular event rate.